EFFICACY AND TOLERABILITY OF TIP (PACLITAXEL, IFOSFAMIDE AND CISPLATIN) INCORPORATED INTO INDUCTION CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE- OR POOR-RISK METASTATIC GERM CELL TUMORS

被引：0
|
作者：
Nishikawa, Masatomo
Miyake, Hideaki
Fujisawa, Masato
机构：
来源：
JOURNAL OF UROLOGY | 2015年 / 193卷 / 04期
关键词：
D O I：
10.1016/j.juro.2015.02.415
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP10-14
引用
收藏
页码：E116 / E116
页数：1
相关论文
共 50 条
  • [31] Outcomes of patients treated with paclitaxel, ifosfamide and cisplatin (TIP) for relapsed germ cell tumour (GCT).
    Jafri, Mariam
    Clarke, Helen
    Hutton, Paul
    Cullen, Michael H.
    Porfiri, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] CLINICAL OUTCOME FOLLOWING POST-CHEMOTHERAPY RETROPERITONEAL LYMPHADENECTOMY IN PATIENTS WITH INTERMEDIATE- AND POOR-RISK NONSEMINOMATOUS TESTICULAR TUMORS
    Argirovic, D.
    Argirovic, A.
    Stanic, V.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (06) : 574 - 574
  • [33] Randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
    Zebic, Danka
    Stockler, Martin
    Martin, Andrew
    Pashankar, Farzana
    Tran, Ben
    Mazhar, Danish
    Huddart, Robert
    Wheater, Matthew
    Walpole, Euan
    Dunwoodie, Elaine
    Feldman, Darren
    Birtle, Alison
    Stevanovic, Amanda
    Wyld, David
    Hanning, Fritha
    Grimison, Peter
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 51 - 51
  • [34] Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors
    Nakamura, Terukazu
    Ueda, Takashi
    Oishi, Masakatsu
    Nakanishi, Hiroyuki
    Fujihara, Atsuko
    Naya, Yoshio
    Hongo, Fumiya
    Kamoi, Kazumi
    Okihara, Koji
    Miki, Tsuneharu
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (03) : 288 - 293
  • [35] Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors
    Nonomura, Norio
    Oka, Daizo
    Nishimura, Kazuo
    Nakayama, Masashi
    Inoue, Hitoshi
    Mizutani, Yoichi
    Miki, Tsuneharu
    Okuyama, Akihiko
    INTERNATIONAL JOURNAL OF UROLOGY, 2007, 14 (06) : 527 - 531
  • [36] CISPLATIN-BASED (PVB+M) CHEMOTHERAPY IN GOOD-RISK AND POOR-RISK NONSEMINOMATOUS GERM-CELL TUMORS
    SAIKIA, T
    HEGDE, U
    ADVANI, S
    RAMAKRISHNAN, G
    KULKARNI, J
    DESAI, PB
    JOURNAL OF SURGICAL ONCOLOGY, 1992, 51 (02) : 100 - 103
  • [37] First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of theFLIPPERtrial
    Staehler, Michael
    Panic, Andrej
    Goebell, Peter J.
    Merling, Marie
    Potthoff, Karin
    Herrmann, Edwin
    de Geeter, Patrick
    Vannier, Corinne
    Hogrefe, Cathrin
    Marschner, Norbert
    Gruenwald, Viktor
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (04) : 950 - 960
  • [38] CARBOPLATIN, ETOPOSIDE, AND BLEOMYCIN FOR PATIENTS WITH POOR-RISK GERM-CELL TUMORS
    MOTZER, RJ
    COOPER, K
    GELLER, NL
    PFISTER, DG
    LIN, SY
    BAJORIN, D
    SCHER, HI
    HERR, H
    FAIR, W
    MORSE, M
    SOGANI, P
    WHITMORE, W
    BOSL, GJ
    CANCER, 1990, 65 (11) : 2465 - 2470
  • [39] EFFICACY OF ADJUVANT CHEMOTHERAPY FOR PATIENTS WITH POOR-RISK PRIMITIVE NEUROECTODERMAL TUMORS MEDULLOBLASTOMA
    SIEGEL, KR
    PACKER, RJ
    SUTTON, LN
    BUNIN, GR
    DANGIO, G
    EVANS, AE
    SCHUT, L
    ANNALS OF NEUROLOGY, 1987, 22 (03) : 449 - 449
  • [40] Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors
    Kondagunta, GV
    Bacik, J
    Bajorin, D
    Dobrzynski, D
    Sheinfeld, J
    Motzer, RJ
    Bosl, GJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9290 - 9294
12345